Director dealing

EDX Medical Group PLC

09 January 2026

 

9 January 2026

EDX Medical Group plc · EDX

AQSE: EDX

("EDX Medical" or the "Company")

Director dealing

CAMBRIDGE, UK: EDX Medical Group plc ("EDX Medical", the "Company" or the "Group"), which develops innovative digital diagnostic products and services for the personalised treatment for cancer, heart disease and infectious diseases, today announces that Professor Sir Christopher Evans, founder and Chief Scientific Officer of the Company, purchased 41,780 ordinary shares in the Company on January 8, 2026, at a price per share of 13.00 pence.

This transaction follows the purchase by Professor Evans of 45,500 ordinary shares in the Company, as announced on January 5, 2026, and the earlier purchase of 57,304 ordinary shares in the Company, as announced on January 2, 2026.

Professor Evans now owns 136,161,523 shares in the Company, representing 35.22% of the issued share capital.

The directors of the Company accept responsibility for the contents of this announcement.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Professor Sir Christopher Evans
2	Reason for the notification
a)	Position/status	Board Director / Chief Scientific Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	EDX Medical Group plc
b)	LEI	213800BZVJZTMCZ6DJ63
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of £0.01 each
	Identification code	ISIN: GB00BNDMJS47
b)	Nature of the transaction	Purchase of shares on market
c)	Price(s) and volume(s)
			Price	Volume
			£0.1300	41,780
d)	Aggregated information
	- Aggregated volume	41,780
	- Price	£0.1300
e)	Date of the transaction	2026-01-08
f)	Place of the transaction	AQSG - Aquis Growth Market (Equity)

ENDS

Contacts: 

EDX Medical Group plc
Dr Mike Hudson  (Chief Executive Officer)	[phone]
Oberon Capital
Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking)	[phone]
Media House International
Ramsay Smith Gary McQueen	[phone] [e-mail] [phone] [e-mail]
IFC Advisory (Investor Relations)
Tim Metcalfe Graham Herring	[phone]

Notes to Editors:

About EDX Medical Group plc

The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.

EDX Medical provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.

www.edxmedical.com

 

END